Trials & Tribulations

Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization”
FreeTrials & Tribulations

Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization”

The release of FDA’s draft guidance, “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases,” has been greatly anticipated since June 2021, when FDA announced in its accelerated approval of the KRASG12C inhibitor sotorasib that it would require a randomized, controlled trial comparing the efficacy of the labeled dose (960 mg once daily) to a 75% lower dose (240 mg once daily) as a condition of full regulatory approval (The Cancer Letter, June 11, 2021; April 29, 2022).
All colorectal cancer patients require germline testing at diagnosis and somatic testing at advanced disease diagnosis
Trials & Tribulations

All colorectal cancer patients require germline testing at diagnosis and somatic testing at advanced disease diagnosis

Technological advances are transforming our understanding of cancer, accelerating the evolution of new treatment approaches. In the past decades, researchers deploying new techniques for analyzing DNA have extended our knowledge of inherited genetic abnormalities that can predispose a person to develop colorectal and other cancers. 
Here’s how we can make clinical trials more inclusive
Trials & Tribulations

Here’s how we can make clinical trials more inclusive

Since COVID-19 made its way to the United States, we have seen a stream of worrying news of the pandemic’s impact on cancer care in the U.S., including 9.4 million missed screenings for just about all forms of cancer. While screening rates rebounded in the fall of 2020, there’s a growing concern from oncologists that screenings haven’t returned to pre-pandemic levels for everyone.
Leveraging cutting-edge technology to address the impact of COVID-19 on cancer screening, diagnosis, and treatment
Trials & Tribulations

Leveraging cutting-edge technology to address the impact of COVID-19 on cancer screening, diagnosis, and treatment

The Omicron variant of SARS-CoV-2 is a powerful reminder that the COVID-19 pandemic, now entering its third year, will continue to have personal and public health impacts. This may be especially true for those individuals who unfortunately missed or delayed cancer screening or treatment as a result of the pandemic.